Clinical Trials Directory

Trials / Conditions / Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia

39 registered clinical trials studyying Autoimmune Hemolytic Anemia18 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingResearch on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia
NCT07453836
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingUCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
NCT07441525
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEARLY_Phase 1
Not Yet RecruitingA Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07287930
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPhase 1
RecruitingA Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493
Keymed Biosciences Co.LtdPhase 1 / Phase 2
Not Yet RecruitingA Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antib
NCT07190261
Bing HanPhase 2
Not Yet RecruitingA Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmun
NCT07149818
Peking Union Medical College Hospital
Not Yet RecruitingUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738
Changzhou No.2 People's HospitalPhase 1
RecruitingBrain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
NCT06921980
Institute of Hematology & Blood Diseases Hospital, China
Not Yet RecruitingA Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT06770504
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
CompletedA Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07075484
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.
NCT06733610
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
RecruitingSafety Study of CC312 in Autoimmune Disease Patients
NCT06888960
CytoCares IncEARLY_Phase 1
Active Not RecruitingCNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
NCT06231368
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
UnknownCAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
NCT06212154
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
RecruitingIbrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
NCT05694312
Gruppo Italiano Malattie EMatologiche dell'AdultoPhase 2
UnknownPresence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patie
NCT05711264
Assiut University
TerminatedPI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More
NCT05676697
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
Not Yet RecruitingThe Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic
NCT04814394
Assiut University
RecruitingEfficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune He
NCT05089227
Centre Hospitalier Universitaire DijonPhase 2
UnknownA Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmu
NCT05263817
Zhejiang UniversityEARLY_Phase 1
UnknownReappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
NCT05057481
Assiut UniversityPhase 3
Active Not RecruitingAcalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic
NCT04657094
City of Hope Medical CenterPhase 2
WithdrawnA Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP
NCT04039477
Kezar Life Sciences, Inc.Phase 2
CompletedSingle-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia
NCT04083014
Peking Union Medical College HospitalPhase 2
UnknownData Registry of Auto Immune Hemolytic Anemia
NCT04024202
Sanquin Research & Blood Bank Divisions
RecruitingProspective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune
NCT05931718
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
UnknownTacrolimus Treatment for Refractory Autoimmune Cytopenia
NCT03918265
Peking Union Medical College HospitalPhase 4
RecruitingBiological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia
NCT04005638
University Hospital, Bordeaux
CompletedA Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
NCT03538041
Incyte CorporationPhase 2
CompletedSevere Immune Cytopenia Registry Www.Sic-reg.Org
NCT03576742
Medical University of Graz
CompletedClinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
NCT03269292
Assiut University
CompletedEvaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventi
NCT02389231
University Hospital, BordeauxPhase 1 / Phase 2
CompletedRole of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
NCT02828670
Centre Hospitalier Universitaire Dijon
CompletedBalance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
NCT04057703
University Hospital, Bordeaux
CompletedImmunopathology of Autoimmune Hemolytic Anemia
NCT02158195
Centre Hospitalier Universitaire Dijon
RecruitingFrench Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
NCT02877706
University Hospital, Toulouse
CompletedBendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
NCT02689986
Helse FonnaPhase 2
RecruitingOBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
NCT05937828
University Hospital, Bordeaux
CompletedTreatment of Autoimmune Thrombocytopenia (AITP)
NCT00001630
National Heart, Lung, and Blood Institute (NHLBI)Phase 1